GSK's (US) Pembrolizumab Injection in China for new indication

Today (February 11), the latest official announcement on the CDE's website shows that GSK's (GSK.US) mepolizumab injection for the treatment of IL-5, a biopharmaceutical 2.2 class, has been accepted for review. According to GSK's website and public information, the indication for mepolizumab's application for market approval in China may be chronic obstructive pulmonary disease (COPD). Mepolizumab has not been approved globally for this indication. The screenshot source is the CDE's website. Interleukin-5 (IL-5) is a cytokine that regulates the growth, activation, and survival of eosinophils and provides important signals for the migration of eosinophils from the bone marrow to the lungs and other organs. Public information shows that mepolizumab (mepolizumab) is the first approved anti-IL-5 monoclonal antibody in the world. It binds to IL-5, blocking its binding to the receptor on the surface of eosinophils, inhibiting the biological activity of eosinophils and reducing their number to normal levels, reducing the growth of eosinophils and the inflammation and tissue damage mediated by eosinophils, and maintaining a healthy state.